Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Type 2 Diabetes Market to Grow Rapidly, Predicts DelveInsight | Key Companies Active in the Domain - Eli Lilly and Company, Regor, AstraZeneca, Eccogene, Pfizer, Novo Nordisk, Novartis, Amgen, MediciNova

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

20 Jun, 2023, 21:15 GMT

Share this article

Share toX

Share this article

Share toX

The type 2 diabetes market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and increased healthcare spending across the world. The high prevalence of the disease and the participation of key companies will bring a change in the type 2 diabetes market dynamics

LAS VEGAS, June 20, 2023 /PRNewswire/ -- DelveInsight's Type 2 Diabetes Market Insights report includes a comprehensive understanding of current treatment practices, type 2 diabetes emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Type 2 Diabetes Market Report

  • As per DelveInsight analysis, the type 2 diabetes market is expected to grow positively at a significant CAGR during the study period (2019–2032).
  • According to the Centers for Disease Control and Prevention, more than 34 million Americans have diabetes (about 1 in 10), and approximately 90-95% of them have type 2 diabetes. Type 2 diabetes most often develops in people over age 45, but more and more children, teens, and young adults are also developing it.
  • Leading type 2 diabetes companies such as Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others are developing novel type 2 diabetes drugs that can be available in the type 2 diabetes market in the coming years.
  • Some key therapies for type 2 diabetes treatment include Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others.
  • Several emerging type 2 diabetes therapies are in their clinical trials' mid and late phases and are awaiting a launch to make the pipeline robust.

Discover which therapies are expected to grab the major type 2 diabetes market share @ Type 2 Diabetes Market Report

Type 2 Diabetes Overview

The most prevalent type of diabetes is type 2 diabetes, which is a disease that happens when blood glucose, commonly known as blood sugar, is too high. This type of diabetes is more common in people in their forties and fifties. It was previously known as adult-onset diabetes. However, type 2 diabetes affects children and adolescents, primarily as a result of childhood obesity. Type 2 diabetes symptoms might be so minor that they go unnoticed. The visual indications and symptoms of this clinical illness include unexplained hunger and weight loss, frequent urination, dry skin, feeling weary all the time, and so on. Fasting plasma glucose (FPG) test, A1C test, random plasma glucose (RPG), and oral glucose tolerance test are used to confirm type 2 diabetes. The normal range for A1C is less than 5.7%, fasting plasma glucose is 99 mg/dL or less, and oral glucose tolerance is 139 mg/dL or less.

Type 2 Diabetes Epidemiology Segmentation

The type 2 diabetes epidemiology section provides insights into the historical and current type 2 diabetes patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The type 2 diabetes market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Type 2 Diabetes Prevalent Cases 
  • Total Type 2 Diabetes Diagnosed Prevalent Cases
  • Total Type 2 Diabetes Gender-specific Prevalent Cases
  • Total Type 2 Diabetes Age-specific Prevalent Diagnosed Cases
  • Type 2 Diabetes Treated Cases

Type 2 Diabetes Treatment Market 

Given the chronic and severe nature of type 1 diabetes and type 2 diabetes, the therapeutic approach for them is extremely thorough; regularisation of glucose metabolism and control of risk factors (e.g., arterial hypertension) is the primary therapy objective for type 2 diabetes. Metformin, the most widely prescribed initial treatment for the illness, decreases blood sugar levels in patients by improving how their bodies manage insulin. Many other medications, such as alpha-glucosidase inhibitors, Amylin analogs or agonists, and sodium-glucose cotransporter-2 inhibitors, are used for type 2 diabetes treatment.

Finerenone, the first nonsteroidal, selective mineralocorticoid receptor (MR) antagonist marketed by Bayer under the brand name Kerendia, received FDA clearance in July 2021. The FDA approved finerenone based on the good results of the pivotal Phase III FIDELIO-DKD research, which was presented during the American Society of Nephrology's (ASN) Kidney Week Reimagined 2020. Finerenone was also authorized by the European Medicines Agency (EMA) in February 2022 to treat chronic renal disease in individuals with type 2 diabetes.

Sumitomo Dainippon Pharma announced the approval of Twymeeg (imegliminhydrochloride) for the treatment of type 2 diabetes in Japan in June 2021. Twymeeg is a first-in-class medication with a novel dual mode of action for the treatment of Type 2 Diabetes throughout the existing treatment paradigm, both as a monotherapy and as an adjunct to conventional glucose-lowering medicines. The medication was developed in conjunction with Poxel.

To know more about type 2 diabetes treatment, visit @ Type 2 Diabetes Treatment Drugs 

Key Type 2 Diabetes Therapies and Companies

  • Tirzepatide/LY3298176: Eli Lilly and Company
  • Danuglipron: Pfizer
  • RGT001-075: Regor Pharmaceuticals Inc.
  • AZD0186: AstraZeneca
  • ECC5004: Eccogene
  • PF-07081532: Pfizer
  • XW014: Sciwind Biosciences USA Co., Ltd.
  • MN-001: MediciNova
  • SPI-62: Sparrow Pharmaceuticals
  • HTD1801: HighTide Biopharma Pty Ltd
  • Semaglutide: Novo Nordisk A/S
  • BMF-219: Biomea Fusion Inc.
  • ALT-801: Altimmune, Inc.
  • MBL949: Novartis
  • LY3457263: Eli Lilly and Company
  • AMG 133: Amgen
  • DD01: Neuraly, Inc.
  • CT-868: Carmot Therapeutics, Inc.
  • IVA337: Inventiva Pharma
  • INV-202: Inversago Pharma Inc
  • AT-001: Applied Therapeutics, Inc.

Learn more about the FDA-approved drugs for type 2 diabetes @ Drugs for Type 2 Diabetes Treatment 

Type 2 Diabetes Market Dynamics

The dynamics of the type 2 diabetes market are expected to change in the coming years. The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate are likely to boost the growth of the type 2 diabetes market in the 7MM. Moreover, the pipeline for type 2 diabetes is quite robust; many prospective therapies are being researched for type 2 diabetes treatment, and it is safe to expect that the type 2 diabetes treatment space will have a substantial impact on the type 2 diabetes market throughout the forecast period. Moreover, the available therapeutics treatment options in the type 2 diabetes landscape aim to provide a cure to the patients suffering from this indication; however, there are several challenges that are yet to be tackled.

However, several factors are impeding the growth of the type 2 diabetes market. The type 2 diabetes market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the type 2 diabetes market growth. 

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Key Type 2 Diabetes Companies

Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others

Key Type 2 Diabetes Therapies

Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others

Scope of the Type 2 Diabetes Market Report

  • Therapeutic Assessment: Type 2 Diabetes current marketed and emerging therapies
  • Type 2 Diabetes Market Dynamics: Attribute Analysis of Emerging Type 2 Diabetes Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's Views, Analyst's Views, Type 2 Diabetes Market Access and Reimbursement

Discover more about type 2 diabetes drugs in development @ Type 2 Diabetes Clinical Trials

Table of Contents

1.

Type 2 Diabetes Market Key Insights

2.

Type 2 Diabetes Market Report Introduction

3.

Type 2 Diabetes Market Overview at a Glance

4.

Type 2 Diabetes Market Executive Summary

5.

Disease Background and Overview

6.

Type 2 Diabetes Treatment and Management

7.

Type 2 Diabetes Epidemiology and Patient Population

8.

Patient Journey

9.

Type 2 Diabetes Marketed Drugs

10.

Type 2 Diabetes Emerging Drugs

11.

Seven Major Type 2 Diabetes Market Analysis

12.

Type 2 Diabetes Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Unmet Needs

16.

SWOT Analysis

17.

Appendix

18.

DelveInsight Capabilities

19.

Disclaimer

20.

About DelveInsight

Related Reports

Type 2 Diabetes Pipeline

Type 2 Diabetes Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, Novartis, among others.

Diabetes Market

Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.

Type 1 Diabetes Market

Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies including Histogen, Novo Nordisk, Prevention Bio, among others.

Diabetes Pipeline

Diabetes Pipeline Insights – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetes companies, including Prevention Bio,  Zealand Pharma, Novo Nordisk, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+1(919)321-6187 

www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.